Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIK2 | Q9H0K1 | 2/20 | 0.40 |
| ▸ | SIK1 | P57059 | 1/20 | 0.40 |
| ▸ | SIK3 | Q9Y2K2 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 2/20 | 0.35 |
| ▸ | HTR2C | P28335 | 2/20 | 0.35 |
| ▸ | HTR2B | P41595 | 2/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 4/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CSF1R | P07333 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 2/20 | 0.32 |
| ▸ | GRM5 | P41594 | 2/20 | 0.31 |
| ▸ | KLK7 | P49862 | 1/20 | 0.31 |
| ▸ | PDE4A | P27815 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29677035 | 1.00 | SIK2 (0.40) | SIK2SIK1SIK3HTR2AHTR2C | |
| SCHEMBL23162267 | 0.91 | SIK1 (0.36) | SIK2SIK1SIK3HTR2AHTR2C | |
| SCHEMBL28585838 | 0.84 | MEN1 (0.46) | SIK2SIK1SIK3PARP1MEN1 | |
| SCHEMBL32691396 | 0.78 | SIK2 (0.40) | SIK2SIK1SIK3MEN1KMT2A | |
| SCHEMBL22747322 | 0.78 | SIK2 (0.51) | SIK2SIK1SIK3CSF1R | |
| SCHEMBL26106783 | 0.77 | CRBN (0.45) | — | |
| SCHEMBL21593334 | 0.76 | SIK1 (0.42) | SIK2SIK1SIK3HTR2AHTR2C | |
| SCHEMBL32691486 | 0.76 | GRM5 (0.41) | SIK2KMT2AALDH1A1GRM5PDE4A | |
| SCHEMBL32691329 | 0.74 | SIK2 (0.38) | SIK2SIK1SIK3KDM4EALDH1A1 | |
| SCHEMBL23162345 | 0.74 | CSF1R (0.34) | MAPTCSF1RBACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12065443-B2 | Compounds and pharmaceutical compositions thereof for the treatment of diseases | GALAPAGOS NV (BE) | 2024-08-20 | — | — | US | disclosed |
| CN-111433200-B | Compounds and pharmaceutical compositions for the treatment of diseases | 加拉帕戈斯股份有限公司 | 2024-03-22 | — | — | CN | disclosed |
| US-20220340581-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES | GALAPAGOS NV (BE) | 2022-10-27 | — | — | US | disclosed |
| US-11339166-B2 | Compounds and pharmaceutical compositions thereof for the treatment of diseases | GALAPAGOS NV (BE) | 2022-05-24 | — | — | US | disclosed |
| US-11339166-B2 | Compounds and pharmaceutical compositions thereof for the treatment of diseases | GALAPAGOS NV (BE) | 2022-05-24 | — | — | US | disclosed |
| EP-3717471-B1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES | GALAPAGOS NV (BE) | 2022-01-05 | — | — | EP | disclosed |
| US-20210101903-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES | GALAPAGOS NV (BE) | 2021-04-08 | — | — | US | disclosed |
| US-20210101903-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES | GALAPAGOS NV (BE) | 2021-04-08 | — | — | US | disclosed |
| EP-3717471-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES | Galapagos NV (BE) | 2020-10-07 | — | — | EP | disclosed |
| CN-111433200-A | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases | 加拉帕戈斯股份有限公司 | 2020-07-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11339166-B2 | Compounds and pharmaceutical compositions thereof for the treatment of diseases | F12, F3, COL1A1 | SIK2 4122/4885SIK1 3852/4885SIK3 1967/4885 |
| US-12065443-B2 | Compounds and pharmaceutical compositions thereof for the treatment of diseases | F12, F3, COL1A1 | SIK2 4122/4885SIK1 3852/4885SIK3 1967/4885 |
| US-20220340581-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES | F12, F3, COL1A1 | SIK2 4122/4885SIK1 3852/4885SIK3 1967/4885 |
| US-20210101903-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES | JAK3, IFNG, IL23R | SIK2 4246/4885SIK1 3947/4885SIK3 2196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.